Zynerba Pharmaceuticals Announces the Acceptance of Two Posters at the Virtual Joint 49th Annual Child Neurology Society & 16th International Child Neurology Society Congress (CNS-ICNA) Meeting

Rhea-AI Summary

Zynerba Pharmaceuticals (NASDAQ:ZYNE) announced the acceptance of two posters for the virtual Joint 49th Annual Child Neurology Society & 16th International Child Neurology Society Congress (CNS-ICNA) from October 12-23, 2020. The posters focus on ZYN002, a transdermal cannabidiol gel, addressing its role in Fragile X Syndrome and its efficacy in Autism Spectrum Disorder. The data aims to explore disease severity and treatment tolerability in children and adolescents. Full posters will be available on the company's website during the event.

Positive

• Presentation of two key research posters at a prestigious virtual conference.
• Focus on therapies for rare neuropsychiatric disorders like Fragile X Syndrome and Autism.

Negative

• None.

DEVON, Pa., Oct. 08, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today has announced the acceptance and presentation details of two posters at the virtual Joint 49^th Annual Child Neurology Society & 16^th International Child Neurology Society Congress (CNS-ICNA) Meeting. The CNS-ICNA annual meeting is being held virtually from October 12^th through October 23^rd, 2020. A copy of the posters will be made available on the Zynerba corporate website at the time of presentation on Monday October 12^th at http://zynerba.com/publications/.

Title: "ZYN002 Cannabidiol Transdermal Gel in Children and Adolescents With Fragile X Syndrome: Role of Methylation Status as a Correlate to Disease Severity and as a Prognostic Biomarker"
Abstract number: 0406 0585 000889
Primary keyword: “Cognitive/Behavioral Disorders (including Autism)”
Poster number: 678

Title: "Tolerability and Efficacy of ZYN002 Cannabidiol (CBD) Transdermal Gel in Children and Adolescents With Autism Spectrum Disorder: An Open-Label Phase 2 Study [BRIGHT (ZYN2-CL-030)]”
Abstract number: 0406 0585 000888
Primary keyword: “Cognitive/Behavioral Disorders (including Autism)”
Poster number: 677

About Zynerba Pharmaceuticals, Inc.
Zynerba Pharmaceuticals is the leader in pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. We are committed to improving the lives of patients and their families living with severe, chronic health conditions including Fragile X syndrome, autism spectrum disorder, 22q11.2 deletion syndrome, and a heterogeneous group of rare and ultra-rare epilepsies known as developmental and epileptic encephalopathies. Learn more at www.zynerba.com and follow us on Twitter at @ZynerbaPharma.

Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from the Company’s current expectations. These and other risks are described in the Company’s periodic reports, including the annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, filed with or furnished to the Securities and Exchange Commission and available at www.sec.gov. Any forward-looking statements that the Company makes in this press release speak only as of the date of this press release. The Company assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

Zynerba Contact
Will Roberts, VP Investor Relations and Corporate Communications
484.581.7489
robertsw@zynerba.com

Media contact
Molly Devlin
Evoke KYNE
215.928.2199
Molly.Devlin@evokegroup.com

FAQ

What is Zynerba Pharmaceuticals presenting at the CNS-ICNA Meeting?

Zynerba Pharmaceuticals is presenting two posters on their transdermal cannabidiol gel, ZYN002, focusing on its applications in Fragile X Syndrome and Autism Spectrum Disorder.

When is the CNS-ICNA Congress taking place?

The CNS-ICNA Congress is scheduled from October 12 to October 23, 2020.

What is the focus of the posters presented by Zynerba Pharmaceuticals?

The posters focus on the role of methylation status in Fragile X Syndrome and the tolerability and efficacy of ZYN002 in Autism Spectrum Disorder.

Where can I find the posters presented by Zynerba Pharmaceuticals?

The posters will be available on Zynerba Pharmaceuticals' corporate website at the time of their presentation on October 12, 2020.

What is ZYN002?

ZYN002 is a transdermal cannabidiol gel developed by Zynerba Pharmaceuticals for treating rare and near-rare neuropsychiatric disorders.